RUNX3 and cancer: We analyzed 263 patients pooled in 4 studies to assess whether the aberrant RUNX3 methylation/expression in serum/cancer tissues DNA was associated with advanced stage, including tumor size (T1–T2 vs T3–T4), lymph node involvement, lymph and blood vessels metastasis, and recurrence in esophageal carcinomas.